Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (1-10 of 159) with videos related to

Pageof 16
Sort By:
The Journal of Infusional Chemotherapy|January 1, 1995
The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practicesE K Rowinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999
On pushing the outer edge of the outer edge of paclitaxel's dosing envelopeE K Rowinsky
Drugs|December 29, 2000
The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agentsE K Rowinsky
Annual Review of Medicine|January 1, 1997
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agentsE K Rowinsky
Oncology (Williston Park, N.Y.)|March 1, 1997
The taxanes: dosing and scheduling considerationsE K Rowinsky
Current Opinion in Oncology|December 1, 1991
Current developments in antitumor antibiotics, epipodophyllotoxins, and vinca alkaloidsE K Rowinsky
Journal of the National Cancer Institute. Monographs|January 1, 1993
Clinical pharmacology of TaxolE K Rowinsky
The Annals of Pharmacotherapy|May 1, 1994
Update on the antitumor activity of paclitaxel in clinical trialsE K Rowinsky
Seminars in Oncology|January 14, 1998
Paclitaxel pharmacology and other tumor typesE K Rowinsky
Oncology (Williston Park, N.Y.)|November 7, 1999
Novel radiation sensitizers targeting tissue hypoxiaE K Rowinsky
Pageof 16

Showing results (1-10 of 159) with videos related to

Sort By:
Pageof 16
The Journal of Infusional Chemotherapy|January 1, 1995
The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practicesE K Rowinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1999
On pushing the outer edge of the outer edge of paclitaxel's dosing envelopeE K Rowinsky
Drugs|December 29, 2000
The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agentsE K Rowinsky
Annual Review of Medicine|January 1, 1997
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agentsE K Rowinsky
Oncology (Williston Park, N.Y.)|March 1, 1997
The taxanes: dosing and scheduling considerationsE K Rowinsky
Current Opinion in Oncology|December 1, 1991
Current developments in antitumor antibiotics, epipodophyllotoxins, and vinca alkaloidsE K Rowinsky
Journal of the National Cancer Institute. Monographs|January 1, 1993
Clinical pharmacology of TaxolE K Rowinsky
The Annals of Pharmacotherapy|May 1, 1994
Update on the antitumor activity of paclitaxel in clinical trialsE K Rowinsky
Seminars in Oncology|January 14, 1998
Paclitaxel pharmacology and other tumor typesE K Rowinsky
Oncology (Williston Park, N.Y.)|November 7, 1999
Novel radiation sensitizers targeting tissue hypoxiaE K Rowinsky
Pageof 16